Cincinnati Children's Hospital- Heart Institute
Cincinnati, Ohio, 45229, United States
NCT Number: NCT07666048
The goal of this clinical trial is to test the effectiveness and implementation of enhanced Secondary Antibiotic Prophylaxis (SAP) supports using a hybrid type 1 effectiveness-implementation design. The purpose is to determine whether enhanced SAP supports will increase average SAP adherence in Brazil and Timor-Leste. The study will enroll people living with Rheumatic Heart Disease (RHD) and Community Health Workers (CHWs) participating in the intervention.
The main questions it aims to answer are:
* Whether CHW-led supports delivered within the community improve mean SAP adherence at 12 months post-intervention. * Whether the intervention demonstrates acceptability, feasibility, uptake and engagement.
Researchers will compare baseline and post-intervention SAP adherence data for the 12 months prior to and following intervention rollout to see if CHW-delivered supports increase adherence.
Trial opening soon.
Get NotifiedAll sexes
Observational
Cincinnati, Ohio, 45229, United States
The first aim will utilize a non-controlled, pre-post design to evaluate CHW-led supports delivered within the community on SAP adherence. The composition of the SAP adherence supports will be finalized prior to implementation and will be comprised of a CHW-delivered package of supports covering patient reminders, education, and connection to care. The final package will reflect solutions that are easy for CHWs to deliver, acceptable to patients and families, and well aligned with local context, resources, and cultural norms. SAP adherence for the 12 months prior to and following intervention rollout will be captured from facility-based paper records, triangulated with prophylaxis cards of individual patients and the ACT registry once it is established at both sites. At enrollment, each participant will be assigned an anonymized study ID, and demographic data will be collected along with RHD history. CHWs in a ratio of approximately 1:10 patients will be selected for training, with training delivered through a standardized, competency-based curriculum including in-person workshops, practical skill-building sessions, and supervised field practice. Ongoing mentorship will be provided throughout the training period to ensure readiness, fidelity, and confidence before CHWs deliver the intervention.
The second aim will be guided by the Integrative Behavioral Model to examine implementation outcomes and mechanisms underlying behavior change related to SAP adherence. A subset of relevant constructs from the outer and inner setting domains of the Consolidated Framework for Implementation Research will augment the IBM. Participants will include people living with RHD, CHWs, and key informants. Quantitative data collection will include program activity logs completed weekly by participating CHWs and a patient knowledge and perception survey developed locally based on the General Attitudes Towards Medication Questionnaire with additional questions capturing IBM constructs. Semi-structured qualitative interviews will follow best practices, including recording with consent, post-interview debriefing, ongoing reflexivity memoing, and maintenance of detailed memos and field notes. Interview guides informed by the IBM and selected CFIR constructs will address perspectives related to acceptability, feasibility, uptake, and engagement.
Quantitative and qualitative analyses will occur in parallel. Descriptive statistics will summarize survey results and aggregate measures of patient engagement and CHW adoption. Joint displays will be constructed to visually compare qualitative and quantitative findings and examine convergence in themes or patterns. Qualitative data will be analyzed using thematic content analysis, with a codebook developed based on the IBM, CFIR, and open coding of initial interviews. All transcripts will be independently coded deductively by one study team member and reviewed by another, with disagreements resolved by consensus.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A CHW-delivered package of supports covering patient reminders, education, and connection to care. The final composition of the SAP adherence supports will be finalized prior to implementation to ensure alignment with local context, resources, and cultural norms. CHWs will be trained using a standardized, competency-based curriculum including in-person workshops, practical skill-building sessions, supervised field practice, and ongoing mentorship to ensure readiness, fidelity, and confidence before delivering the supports.
Time frame: 24 months
Proportion of participants reporting the intervention as acceptable (e.g., via standardized acceptability surveys)
Proportion of intended intervention components successfully implemented (fidelity/adoption)
Time frame: 12 months
Receipt of ≥80% of scheduled secondary antibiotic prophylaxis injections
Time frame: 2 months
Frequency of response to SMS reminders Participation in peer group activities Completion of scheduled CHW contacts
Time frame: 5 months
Documented modifications using human-centered design methods (e.g., interviews, co-design workshops)
Time frame: 5 months
Proportion of planned CHW activities completed CHW-reported ease of delivery (survey/interviews)
Contact information is provided by the study sponsor or research team.
Isabella Brigham, Bachelor of Science
CONTACT
Principal Investigator, Assistant Professor
CONTACT
Children's Hospital Medical Center, Cincinnati
Other
Acronym: SHIELD 3 Adapt
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07078357
Arthritis, Bacterial Infections
São Paulo, Brazil
View Trial DetailsNCT07603297
Bacterial Infections, Bacterial Infections and Mycoses
Tororo, Uganda
View Trial DetailsNCT06720272
Arthritis, Bacterial Infections
Kathmandu, Nepal
View Trial DetailsNCT05504928
Bacterial Infections, Bacterial Infections and Mycoses
Tulsi̇̄pur, Nepal
View Trial Details